The Management Team
Alexei was initially trained and did research work in the field of Plasma Physics in Moscow. Subsequently, he worked as a producer for Sat.1, NBC News and CNBC in Russia. In 1998, he moved to the UK and completed an MSc programme in Global Market Economics at the London School of Economics. He then worked as a consultant/country economist in the office of the Chief Economist of the European Bank for Reconstruction and Development and as an EEMEA analyst at Dresdner Kleinwort Wasserstein. He continued his career working as a partner at ASI International Consulting and Intelleca.
Andrew M Jackson (PhD)
Andrew is Associate Professor of Cancer Immunology at the University of Nottingham and has over 25 years of experience in biomedical research. Andrew undertook his PhD at Edinburgh University in 1989 and has since lead research teams at ICRF/CRUK Leeds University (UK), Duke University (USA) and Nottingham University (UK) where he presently leads the Host-Tumour Interactions Group in the Division of Cancer and Stem Cells at the School of Medicine. He was involved in the development of anti-TNF strategies for treatment of Rheumatoid Arthritis in the 1980s and in the 1990s developed the background research for number of first-in-man clinical trials of novel DNA-vaccines for Melanoma and Breast Cancer. His academic research interests focus on the immuno-biology of malignant melanoma of the skin and in particular intracellular signalling pathways in Dendritic Cells. Andrew is a member of the Editorial Board of the Future Medicine journal Immunotherapy and has published more than 70 peer-reviewed research papers, review articles and book chapters.
Dr Anton Alexandroff (PhD)
Anton is currently an Honorary Senior Lecturer at De Montfort University and Consultant Dermatologist at Skin55 Harley St. London, Cambridge Nuffield Health, Cambridge Spire Lea and Leicester Nuffield Health hospitals. He began his research career with post-graduate studies at Edinburgh University in 1991 in the field of Cancer Immunology and has since published over 40 peer-reviewed research papers and reviews, on 30 of which he is lead or senior author. He is a member of British Association of Dermatologists, American Academy of Dermatology (International Fellow), European Society for Cosmetic and Aesthetic Dermatology, British Society for Dermatological Surgery, and UK Dermatology Clinical Trials Network. Anton is a member of the Honorary Editorial Board of the journals Clinical, Cosmetic and Investigational Dermatology and Journal of Allergy & Therapy.
Chief Investment Officer
Julian is an experienced business development specialist who has managed multibillion transactions.
After graduating as an economist, has devised and successfully implemented commercial initiatives for Mitsui, APV, PWC, Taylor Woodrow, Mosenergo, MMK, IBM Consulting, Landis & Gyr, DME and many other international organisations.
The Advisory Board
Professor Robin Graham-Brown
Robin is an Emeritus Consultant and Honorary Senior Lecturer at the University Hospitals of Leicester. He has extensive expertise in all areas of dermatology, paediatric dermatology, eczema, acne and skin cancer. He was the editor of The British Journal of Dermatology 2000-2004, President of the British Association of Dermatologists 2005-2006 and Chairman of the Department of Health Working Party on Dermatology Closer to Home 2006-2008. He is also now Honorary Secretary of the British Skin Foundation, Chairman of the Development Board of the University of Leicester, a member of the Executive Committee of the British Association of Dermatologists, and a Member of Royal Society of Medicine, and Fellow of American Academy of Dermatology.
Professor Poulam M Patel
Poulam is the Professor of Clinical Oncology and Honorary Consultant Medical Oncologist at Nottingham University Hospitals NHS Trust. He is Chair of the EORTC Melanoma Study Group and currently serves as advisor to a number of pharmaceutical companies and clinical-studies bodies. His research interests include the immunology of skin-cancer (malignant melanoma), novel cancer vaccines and immunotherapeutic approaches to malignancy. He has published over 60 papers covering basic research in tumour immunology and clinical trials in a range of tumours including first-in-man phase I trials.